These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 21907778)

  • 1. Cationic solid lipid nanoparticles (cSLN): structure, stability and DNA binding capacity correlation studies.
    Doktorovova S; Shegokar R; Rakovsky E; Gonzalez-Mira E; Lopes CM; Silva AM; Martins-Lopes P; Muller RH; Souto EB
    Int J Pharm; 2011 Nov; 420(2):341-9. PubMed ID: 21907778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC): effects on size, physical stability and particle matrix structure.
    Kovacevic A; Savic S; Vuleta G; Müller RH; Keck CM
    Int J Pharm; 2011 Mar; 406(1-2):163-72. PubMed ID: 21219990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of surface-modified solid lipid nanocontainers formulated with a heterolipid-templated homolipid.
    Attama AA; Müller-Goymann CC
    Int J Pharm; 2007 Apr; 334(1-2):179-89. PubMed ID: 17140752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stability of lipid excipients in solid lipid nanoparticles.
    Radomska-Soukharev A
    Adv Drug Deliv Rev; 2007 Jul; 59(6):411-8. PubMed ID: 17553589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement in antifungal activity of eugenol in immunosuppressed rats through lipid nanocarriers.
    Garg A; Singh S
    Colloids Surf B Biointerfaces; 2011 Oct; 87(2):280-8. PubMed ID: 21689909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-destructive methods of characterization of risperidone solid lipid nanoparticles.
    Rahman Z; Zidan AS; Khan MA
    Eur J Pharm Biopharm; 2010 Sep; 76(1):127-37. PubMed ID: 20470882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Solid lipid nanodispersions containing mixed lipid core and a polar heterolipid: characterization.
    Attama AA; Schicke BC; Paepenmüller T; Müller-Goymann CC
    Eur J Pharm Biopharm; 2007 Aug; 67(1):48-57. PubMed ID: 17276663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation, characterization, and evaluation of gatifloxacin loaded solid lipid nanoparticles as colloidal ocular drug delivery system.
    Kalam MA; Sultana Y; Ali A; Aqil M; Mishra AK; Chuttani K
    J Drug Target; 2010 Apr; 18(3):191-204. PubMed ID: 19839712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Production & stability of stavudine solid lipid nanoparticles--from lab to industrial scale.
    Shegokar R; Singh KK; Müller RH
    Int J Pharm; 2011 Sep; 416(2):461-70. PubMed ID: 20727389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. pDNA condensation capacity and in vitro gene delivery properties of cationic solid lipid nanoparticles.
    Vighi E; Ruozi B; Montanari M; Battini R; Leo E
    Int J Pharm; 2010 Apr; 389(1-2):254-61. PubMed ID: 20100555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential scanning calorimetry studies on sunscreen loaded solid lipid nanoparticles prepared by the phase inversion temperature method.
    Montenegro L; Sarpietro MG; Ottimo S; Puglisi G; Castelli F
    Int J Pharm; 2011 Aug; 415(1-2):301-6. PubMed ID: 21679757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid nanocarriers (GeluPearl) containing amphiphilic lipid Gelucire 50/13 as a novel stabilizer: fabrication, characterization and evaluation for oral drug delivery.
    Date AA; Vador N; Jagtap A; Nagarsenker MS
    Nanotechnology; 2011 Jul; 22(27):275102. PubMed ID: 21606564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) -- structural investigations on two different carrier systems.
    Saupe A; Wissing SA; Lenk A; Schmidt C; Müller RH
    Biomed Mater Eng; 2005; 15(5):393-402. PubMed ID: 16179760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanostructured lipid carriers (NLC) on the basis of Siberian pine (Pinus sibirica) seed oil.
    Averina ES; Seewald G; Müller RH; Radnaeva LD; Popov DV
    Pharmazie; 2010 Jan; 65(1):25-31. PubMed ID: 20187575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid nanocarriers for dermal delivery of lutein: preparation, characterization, stability and performance.
    Mitri K; Shegokar R; Gohla S; Anselmi C; Müller RH
    Int J Pharm; 2011 Jul; 414(1-2):267-75. PubMed ID: 21596122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comet assay reveals no genotoxicity risk of cationic solid lipid nanoparticles.
    Doktorovova S; Silva AM; Gaivão I; Souto EB; Teixeira JP; Martins-Lopes P
    J Appl Toxicol; 2014 Apr; 34(4):395-403. PubMed ID: 24243595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting.
    Aji Alex MR; Chacko AJ; Jose S; Souto EB
    Eur J Pharm Sci; 2011 Jan; 42(1-2):11-8. PubMed ID: 20971188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modified Rose Bengal assay for surface hydrophobicity evaluation of cationic solid lipid nanoparticles (cSLN).
    Doktorovova S; Shegokar R; Martins-Lopes P; Silva AM; Lopes CM; Müller RH; Souto EB
    Eur J Pharm Sci; 2012 Apr; 45(5):606-12. PubMed ID: 22245537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Employment of cationic solid-lipid nanoparticles as RNA carriers.
    Montana G; Bondì ML; Carrotta R; Picone P; Craparo EF; San Biagio PL; Giammona G; Di Carlo M
    Bioconjug Chem; 2007; 18(2):302-8. PubMed ID: 17253655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re-dispersible cationic solid lipid nanoparticles (SLNs) freeze-dried without cryoprotectors: characterization and ability to bind the pEGFP-plasmid.
    Vighi E; Ruozi B; Montanari M; Battini R; Leo E
    Eur J Pharm Biopharm; 2007 Sep; 67(2):320-8. PubMed ID: 17368876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.